Expression of multidrug resistance-associated protein (MRP) in thyroid cancers

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Anaplastic carcinoma of the thyroid (ATC) exhibits significant anti-cancer drug resistance.
• The role of P-glycoprotein (P-gp) in multidrug resistance (MDR) is well-established, but may not fully explain resistance in ATC.
• Alternative MDR mechanisms, such as those involving other transporter proteins, warrant investigation.

Purpose of the Study:

• To investigate the potential role of the multidrug resistance-associated protein (MRP) in the drug resistance of anaplastic thyroid carcinoma.
• To compare MRP expression levels in anaplastic carcinoma with other types of thyroid cancer.

Main Methods:

• Immunohistochemical analysis was employed to detect MRP expression.
• Samples included 8 thyroid cancer cell lines and 73 surgically resected thyroid cancer tissues.
• Expression levels were quantified and compared across different thyroid cancer subtypes.

Main Results:

• The expression of multidrug resistance-associated protein (MRP) was detected in thyroid cancer.
• MRP was found in 52% of anaplastic carcinoma cases.
• The frequency of MRP expression was significantly higher in anaplastic carcinoma than in other thyroid cancer types.

Conclusions:

• Multidrug resistance-associated protein (MRP) expression is a significant factor in the drug resistance of anaplastic thyroid carcinoma.
• MRP may play a more critical role in ATC drug resistance than P-glycoprotein alone.
• Targeting MRP could be a potential therapeutic strategy for overcoming drug resistance in anaplastic thyroid cancer.